Omnicell, Inc. (NASDAQ:OMCL) has been given an average rating of “Buy” by the twelve research firms that are presently covering the company, MarketBeat reports. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $49.00.

A number of equities analysts have recently commented on the stock. BidaskClub lowered shares of Omnicell from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Piper Jaffray Companies reaffirmed a “hold” rating and set a $40.00 target price on shares of Omnicell in a research report on Sunday, July 30th. Craig Hallum raised their target price on shares of Omnicell from $46.00 to $52.00 and gave the stock a “buy” rating in a research report on Friday, July 28th. Dougherty & Co raised their target price on shares of Omnicell from $45.00 to $49.00 and gave the stock a “buy” rating in a research report on Friday, July 28th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and set a $47.00 target price on shares of Omnicell in a research report on Tuesday, July 25th.

COPYRIGHT VIOLATION NOTICE: “Omnicell, Inc. (NASDAQ:OMCL) Receives Consensus Rating of “Buy” from Analysts” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://www.americanbankingnews.com/2017/08/08/omnicell-inc-nasdaqomcl-receives-consensus-rating-of-buy-from-analysts.html.

In related news, EVP Dan S. Johnston sold 16,400 shares of Omnicell stock in a transaction that occurred on Friday, May 19th. The shares were sold at an average price of $40.67, for a total transaction of $666,988.00. Following the transaction, the executive vice president now directly owns 61,696 shares of the company’s stock, valued at $2,509,176.32. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Chairman Randall A. Lipps sold 9,900 shares of Omnicell stock in a transaction that occurred on Monday, June 5th. The shares were sold at an average price of $43.00, for a total transaction of $425,700.00. Following the transaction, the chairman now directly owns 208,982 shares in the company, valued at $8,986,226. The disclosure for this sale can be found here. Over the last three months, insiders have sold 149,675 shares of company stock worth $6,754,894. 3.77% of the stock is currently owned by corporate insiders.

Institutional investors have recently modified their holdings of the stock. Diversified Trust Co acquired a new position in shares of Omnicell during the first quarter valued at about $228,000. State of Alaska Department of Revenue raised its position in shares of Omnicell by 3.0% in the first quarter. State of Alaska Department of Revenue now owns 4,080 shares of the company’s stock valued at $165,000 after buying an additional 120 shares during the last quarter. Conestoga Capital Advisors LLC raised its position in shares of Omnicell by 12.9% in the first quarter. Conestoga Capital Advisors LLC now owns 1,513,866 shares of the company’s stock valued at $61,539,000 after buying an additional 172,642 shares during the last quarter. SFE Investment Counsel acquired a new position in shares of Omnicell during the first quarter valued at about $332,000. Finally, Legato Capital Management LLC raised its position in shares of Omnicell by 3,965.0% in the first quarter. Legato Capital Management LLC now owns 42,154 shares of the company’s stock valued at $1,037,000 after buying an additional 41,117 shares during the last quarter. 96.35% of the stock is currently owned by institutional investors.

Shares of Omnicell (NASDAQ OMCL) traded down 0.49% on Tuesday, reaching $51.20. The company had a trading volume of 116,586 shares. The stock’s 50 day moving average is $43.70 and its 200 day moving average is $40.34. The firm’s market capitalization is $1.91 billion. Omnicell has a 52 week low of $30.35 and a 52 week high of $51.97.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, July 27th. The company reported $0.02 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.02. The business had revenue of $180.90 million for the quarter, compared to analyst estimates of $174.08 million. Omnicell had a negative net margin of 1.14% and a positive return on equity of 0.41%. The company’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same period last year, the company posted $0.38 earnings per share. On average, equities analysts anticipate that Omnicell will post $1.31 EPS for the current year.

Omnicell Company Profile

Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.

Analyst Recommendations for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.